We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

43 hedge funds and large institutions have $21M invested in CTI BioPharma Corp. (DE) Common Stock in 2019 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 14 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% less capital invested

Capital invested by funds: $23.4M → $21M (-$2.4M)

25% less funds holding

Funds holding: 57 → 43 (-14)

36% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 14

88% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 16

Holders
43
Holders Change
-14
Holders Change %
-24.56%
% of All Funds
0.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
9
Reduced
14
Closed
16
Calls
$34K
Puts
–
Net Calls
+$34K
Net Calls Change
-$74K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$215K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$214K
3
Squarepoint
Squarepoint
New York
+$40.3K
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$7.71K
5
Victory Capital Management
Victory Capital Management
Texas
+$7.48K

Top Sellers

Rank Fund Capital Flow
1
FI
Fosun International
China
-$390K
2
Millennium Management
Millennium Management
New York
-$360K
3
Northern Trust
Northern Trust
Illinois
-$331K
4
Goldman Sachs
Goldman Sachs
New York
-$326K
5
Bank of America
Bank of America
North Carolina
-$161K

CTIC Hedge Fund Activity: Q3 2019 in Review

43 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2019, worth a combined $21M — down 10% from $23.4M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of CTIC and 2 opened new positions — a net loss of 14 holders — while 14 trimmed existing stakes and 9 added.

The largest buyer was Renaissance Technologies, adding an estimated $215K. The largest seller was Fosun International, exiting entirely with an estimated $390K sold.

  • 43 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2019, down from 57 in Q2 2019.
  • Funds reported $21M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2019, down 10% quarter-over-quarter.
  • 2 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2019 and 16 closed out, a net change of -14 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2019 was Renaissance Technologies, an estimated $215K added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2019 was Fosun International, an estimated $390K sold.

Based on aggregated 13F filings for Q3 2019.